The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Research Report 2025
Synopsis
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age-relatedMacularDegeneration (ARMD) Drugs market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 9609.5 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Age-relatedMacularDegeneration (ARMD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-relatedMacularDegeneration (ARMD) Drugs.
Report Scope
The Age-relatedMacularDegeneration (ARMD) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age-relatedMacularDegeneration (ARMD) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age-relatedMacularDegeneration (ARMD) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Segment by Type
Anti VEGF Drugs
Photosensitive Drugs
Others
Segment by Application
Exudative ARMD
Atrophy ARMD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age-relatedMacularDegeneration (ARMD) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age-relatedMacularDegeneration (ARMD) Drugs market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 9609.5 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Age-relatedMacularDegeneration (ARMD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-relatedMacularDegeneration (ARMD) Drugs.
Report Scope
The Age-relatedMacularDegeneration (ARMD) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age-relatedMacularDegeneration (ARMD) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age-relatedMacularDegeneration (ARMD) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Segment by Type
Anti VEGF Drugs
Photosensitive Drugs
Others
Segment by Application
Exudative ARMD
Atrophy ARMD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age-relatedMacularDegeneration (ARMD) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Anti VEGF Drugs
1.2.3 Photosensitive Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Exudative ARMD
1.3.3 Atrophy ARMD
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Perspective (2019-2030)
2.2 Age-relatedMacularDegeneration (ARMD) Drugs Growth Trends by Region
2.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Region (2019-2024)
2.2.3 Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Region (2025-2030)
2.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Dynamics
2.3.1 Age-relatedMacularDegeneration (ARMD) Drugs Industry Trends
2.3.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
2.3.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
2.3.4 Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue
3.1.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue (2019-2024)
3.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Age-relatedMacularDegeneration (ARMD) Drugs Revenue
3.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio
3.4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2023
3.5 Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Area Served
3.6 Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
3.7 Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Type
4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Type (2019-2024)
4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2025-2030)
5 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Application
5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Application (2019-2024)
5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2019-2030)
6.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024)
6.4 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2019-2030)
7.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024)
7.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2019-2030)
8.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2019-2030)
9.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024)
9.4 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2019-2030)
10.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.1.4 Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Regeneron Pharmaceuticals
11.2.1 Regeneron Pharmaceuticals Company Detail
11.2.2 Regeneron Pharmaceuticals Business Overview
11.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.2.4 Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.2.5 Regeneron Pharmaceuticals Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.3.4 Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 Santen Oy
11.4.1 Santen Oy Company Detail
11.4.2 Santen Oy Business Overview
11.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.4.4 Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.4.5 Santen Oy Recent Development
11.5 Kanghong Pharmaceuticals
11.5.1 Kanghong Pharmaceuticals Company Detail
11.5.2 Kanghong Pharmaceuticals Business Overview
11.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.5.4 Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.5.5 Kanghong Pharmaceuticals Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.6.4 Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.7.4 Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.7.5 Eli Lilly and Company Recent Development
11.8 TRACON Pharmaceuticals
11.8.1 TRACON Pharmaceuticals Company Detail
11.8.2 TRACON Pharmaceuticals Business Overview
11.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.8.4 TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.8.5 TRACON Pharmaceuticals Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.9.4 Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 GSK
11.10.1 GSK Company Detail
11.10.2 GSK Business Overview
11.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.10.4 GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.10.5 GSK Recent Development
11.11 BIOCAD
11.11.1 BIOCAD Company Detail
11.11.2 BIOCAD Business Overview
11.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.11.4 BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
11.11.5 BIOCAD Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Anti VEGF Drugs
Table 3. Key Players of Photosensitive Drugs
Table 4. Key Players of Others
Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2019-2024)
Table 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2025-2030)
Table 11. Age-relatedMacularDegeneration (ARMD) Drugs Market Trends
Table 12. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
Table 13. Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
Table 14. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints
Table 15. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players (2019-2024)
Table 17. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2023)
Table 18. Ranking of Global Top Age-relatedMacularDegeneration (ARMD) Drugs Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
Table 22. Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2019-2024)
Table 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2025-2030)
Table 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application (2019-2024)
Table 30. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application (2025-2030)
Table 32. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Roche Company Detail
Table 48. Roche Business Overview
Table 49. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 50. Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Regeneron Pharmaceuticals Company Detail
Table 53. Regeneron Pharmaceuticals Business Overview
Table 54. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 55. Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 56. Regeneron Pharmaceuticals Recent Development
Table 57. Bayer Company Detail
Table 58. Bayer Business Overview
Table 59. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 60. Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 61. Bayer Recent Development
Table 62. Santen Oy Company Detail
Table 63. Santen Oy Business Overview
Table 64. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 65. Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 66. Santen Oy Recent Development
Table 67. Kanghong Pharmaceuticals Company Detail
Table 68. Kanghong Pharmaceuticals Business Overview
Table 69. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 70. Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 71. Kanghong Pharmaceuticals Recent Development
Table 72. Novartis Company Detail
Table 73. Novartis Business Overview
Table 74. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 75. Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 76. Novartis Recent Development
Table 77. Eli Lilly and Company Company Detail
Table 78. Eli Lilly and Company Business Overview
Table 79. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 80. Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 81. Eli Lilly and Company Recent Development
Table 82. TRACON Pharmaceuticals Company Detail
Table 83. TRACON Pharmaceuticals Business Overview
Table 84. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 85. TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 86. TRACON Pharmaceuticals Recent Development
Table 87. Pfizer Company Detail
Table 88. Pfizer Business Overview
Table 89. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 90. Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 91. Pfizer Recent Development
Table 92. GSK Company Detail
Table 93. GSK Business Overview
Table 94. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 95. GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 96. GSK Recent Development
Table 97. BIOCAD Company Detail
Table 98. BIOCAD Business Overview
Table 99. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 100. BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024) & (US$ Million)
Table 101. BIOCAD Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type: 2023 VS 2030
Figure 3. Anti VEGF Drugs Features
Figure 4. Photosensitive Drugs Features
Figure 5. Others Features
Figure 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2023 VS 2030
Figure 8. Exudative ARMD Case Studies
Figure 9. Atrophy ARMD Case Studies
Figure 10. Age-relatedMacularDegeneration (ARMD) Drugs Report Years Considered
Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region: 2023 VS 2030
Figure 14. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players in 2023
Figure 15. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2023
Figure 17. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2019-2030)
Figure 19. United States Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2019-2030)
Figure 23. Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2019-2030)
Figure 31. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2019-2030)
Figure 39. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2019-2030)
Figure 43. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Roche Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 46. Regeneron Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 47. Bayer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 48. Santen Oy Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 49. Kanghong Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 51. Eli Lilly and Company Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 52. TRACON Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 53. Pfizer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 54. GSK Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 55. BIOCAD Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
